Publications by authors named "Ian Pyrah"

Claim this Profile
D
Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody.
Rogely Waite Boyce, Danielle Brown, Melanie Felx, Nacera Mellal, Kathrin Locher, Ian Pyrah

Bone Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.
Scott Taylor, Rong Hu, Efrain Pacheco, Kathrin Locher, Ian Pyrah

Bone Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.
Michael S Ominsky, Steven K Boyd, Aurore Varela, Jacquelin Jolette, Melanie Felx, Ian Pyrah

J Bone Miner Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.
Luc Chouinard, Melanie Felx, Nacera Mellal, Aurora Varela, Peter Mann, Ian Pyrah

Regul Toxicol Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Mark R Fielden, Charles Dean, Kurt Black, Satin G Sawant, Raju Subramanian, Ian Pyrah

Int J Toxicol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Scott Taylor, Michael S Ominsky, Rong Hu, Efrain Pacheco, Yudong D He, Ian Pyrah

Bone· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Michael S Ominsky, Danielle L Brown, Gwyneth Van, David Cordover, Efrain Pacheco, Ian Pyrah

Bone· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
Paul Nioi, Scott Taylor, Rong Hu, Efrain Pacheco, Yudong D He, Ian Pyrah

J Bone Miner Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species.
Dina A Andrews, Ian T G Pyrah, Babette M Boren, Sarah H Tannehill-Gregg, Ruth M Lightfoot-Dunn

Toxicol Pathol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-related differences in the pharmacodynamic and toxicologic response to a novel hyperglycosylated analog of recombinant human erythropoietin in Sprague-Dawley rats with similarly high hematocrit.
Dina A Andrews, Babette M Boren, James R Turk, Rogely W Boyce, Yudong D He, Ian T G Pyrah

Toxicol Pathol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines associated with increased erythropoiesis in Sprague-Dawley rats administered a novel hyperglycosylated analog of recombinant human erythropoietin.
Dina A Andrews, Hisham K Hamadeh, Yudong D He, Babette M Boren, James R Turk, Ian T G Pyrah

Toxicol Pathol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy.
Graeme J Moffat, Rhian Davies, Gayle Kwon, Marc W Retter, Gary J Chellman, Ian T G Pyrah

Reprod Toxicol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.
Rogely W Boyce, Aurore Varela, Luc Chouinard, Jeanine L Bussiere, Gary J Chellman, Ian T Pyrah

Bone· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproductive toxicity of denosumab in cynomolgus monkeys.
Jeanine L Bussiere, Ian Pyrah, Rogely Boyce, Dan Branstetter, Mark Loomis

Reprod Toxicol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Paul J Kostenuik, Susan Y Smith, Jacquelin Jolette, Joseph Schroeder, Ian Pyrah

Bone· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Michael S Ominsky, Brian Stouch, Joseph Schroeder, Ian Pyrah, Marina Stolina

Bone· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global recognition of qualified toxicologic pathologists: credential review as a potential route for recognizing the proficiency of pathologists involved in regulatory-type nonclinical studies.
Robert A Ettlin, Brad Bolon, Ian Pyrah, Yoichi Konishi, Hugh E Black

Exp Toxicol Pathol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The international nomenclature project: an update.
John Vahle, Alys Bradley, Taki Harada, Ron Herbert, Wolfgang Kaufmann, Ian Pyrah

Toxicol Pathol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global recognition of qualified toxicologic pathologists: credential review as a potential route for recognizing the proficiency of pathologists involved in regulatory-type nonclinical studies.
Robert A Ettlin, Brad Bolon, Ian Pyrah, Yoichi Konishi, Hugh E Black

Toxicol Pathol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Recognition of Qualified Toxicologic Pathologists: Credential Review as a Potential Route for Recognizing the Proficiency of Pathologists Involved in Regulatory-type Nonclinical Studies.
Robert A Ettlin, Brad Bolon, Ian Pyrah, Yoichi Konishi, Hugh E Black

J Toxicol Pathol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global recognition of qualified toxicologic pathologists: where we are now and where we need to go.
Robert A Ettlin, Brad Bolon, Ian Pyrah, Yoichi Konishi, Hugh E Black

Toxicol Pathol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global recognition of qualified toxicologic pathologists: where we are now and where we need to go.
Robert A Ettlin, Brad Bolon, Ian Pyrah, Yoichi Konishi, Hugh E Black

Exp Toxicol Pathol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.
Denis Alferez, Robert W Wilkinson, Jim Watkins, Richard Poulsom, Nikki Mandir, Ian T Pyrah

Mol Cancer Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of the application of RNA interference technology in the pharmaceutical industry.
Henny M Martineau, Ian T Pyrah

Toxicol Pathol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis